How BD Teams Track Competitor Pipelines in 2026

If you're in pharma BD, you know the drill. Every week, you:

1. Open ClinicalTrials.gov and search for your therapeutic area
2. Export results to a spreadsheet
3. Filter by phase and status, and manually compare competitors
4. Copy-paste the relevant trials into your pipeline model
5. Repeat next week. And the week after.

Most BD teams spend 4–6 hours per week on competitor pipeline tracking. That's 200+ hours per year — on a task that should take 30 minutes.

In this guide, we'll cover how top pharma BD teams are automating pipeline tracking in 2026, what tools they use, and what separates efficient teams from the rest.

The Pipeline Tracking Problem

ClinicalTrials.gov has over 400,000 registered trials. In a typical therapeutic area like oncology, there might be 5,000–10,000 active trials. Your job is to find the 50–100 that actually matter to your pipeline.

The challenge isn't access to data — it's processing it. Here's what makes manual pipeline tracking so painful:

• Volume: A single search for "NSCLC" returns 3,000+ trials. Manually reviewing them all is impossible.
• Velocity: New trials are added daily. Status changes happen constantly. A static spreadsheet is outdated the moment you finish it.
• Fragmentation: Data lives in CT.gov, company pipelines, conference abstracts, and patent filings. No single source of truth.
• Context: Raw trial data doesn't tell you which competitors are converging on the same endpoint, which indications are underserved, or which assets are acquisition targets.

The real cost isn't the time — it's the missed signals. A competitor's trial status change from "Recruiting" to "Active, not recruiting" might mean they hit enrollment. A new Phase 2 start in your target indication might be a first-mover advantage. Manual tracking misses these.

What Top BD Teams Do Differently

After talking to BD professionals at pharma companies, CROs, and investment firms, here's what separates efficient teams:

1. They Automate the Fetch

Instead of manually searching CT.gov every week, they set up automated data pulls. Options:

• CT.gov's search system: Built-in search with filters for condition, intervention, sponsor, and status. Pull up to 1,000 results at a time.
• Automated scripts: Simple tools that run searches on a schedule, store results, and flag changes.
• Browser tools: Extensions like TrialScope that handle the searching, filtering, and export directly in CT.gov.

The key is not re-searching every week — it's pulling fresh data and comparing it against last week's results.

2. They Filter Before They Read

Raw search results are noise. Efficient teams apply filters before looking at individual trials:

• Phase filter: Only Phase 2/3 trials matter for near-term pipeline impact. Phase 1 is too early, Phase 4 is already approved.
• Status filter: RECRUITING + ACTIVE_NOT_RECRUITING = trials that are actually happening. COMPLETED = check for results.
• Sponsor filter: Exclude academic trials if you're tracking commercial competition.
• Enrollment filter: Trials with < 50 patients are unlikely to move the needle.

The goal: reduce 3,000 results to 50–100 relevant trials before you read a single title.

3. They Track Changes, Not Static Snapshots

The most valuable signal in pipeline tracking is change:

• Trial status change: "Not yet recruiting" → "Recruiting" (competitor is moving)
• Enrollment spike: 50 → 200 patients in one week (fast enrollment = registration intent)
• New trial start: First competitor trial in a new indication (first-mover signal)
• Results posted: COMPLETED + hasResults = data is available (competitive threat or partnership opportunity)

Tools that track these changes and send alerts (browser notifications, email, Slack) are worth their weight in gold. Manual weekly reviews catch changes — but with a 7-day lag.

4. They Use AI to Structure Unstructured Data

CT.gov data is raw and unstructured. A competitor trial's "brief summary" might be 500 words of dense medical text. The "primary outcome" might be vague. The "intervention" might be described in technical jargon.

AI analysis tools can:

• Extract the signal: "This is a Phase 3 EGFR inhibitor with CNS penetration — competitive to osimertinib"
• Score the threat: High/medium/low investment score based on phase, mechanism, and sponsor track record
• Identify gaps: "No Phase 3 trials in renal impairment — underserved population"
• Compare assets: "Comparable to Tagrisso, but with better CNS penetration"

The output is structured data you can drop into pipeline models, board decks, and investment memos.

A Typical BD Pipeline Tracking Workflow

Here's what an efficient weekly pipeline review looks like:

Total time: ~22 minutes. Compare that to the 4+ hours most teams spend.

Key Metrics to Track

Not all competitor trials are equal. Here's how to prioritize:

Phase

• Phase 3: Highest priority. Registration-imminent. Know their endpoints, enrollment, and completion date.
• Phase 2: Medium priority. Proof-of-concept stage. Watch for dose selection and interim results.
• Phase 1: Low priority. Too early to assess commercial impact unless first-in-class mechanism.
• Phase 4: Post-approval. Monitor for label expansions or safety signals.

Sponsor Track Record

A Phase 3 trial from a sponsor with 5 prior NDA approvals is more credible than one from a sponsor with zero approved drugs. Track sponsor class (INDUSTRY vs. NIH vs. academic) and historical success rate.

Enrollment Velocity

Trials that enroll fast are signaling strong site infrastructure and patient access. A trial going from 50 to 300 patients in a month is a registration signal.

Endpoint Differentiation

If a competitor is using the same primary endpoint as the approved standard, they're playing catch-up. If they're using a novel endpoint (e.g., CNS penetration vs. PFS), they might have a differentiation story.

Common Mistakes

Mistake 1: Tracking everything. You can't monitor 5,000 trials. Filter to 50–100 high-relevance trials and track those religiously.

Mistake 2: Ignoring academic trials. Academic trials often publish in top journals and influence guidelines. They can be acquisition targets or partnership opportunities.

Mistake 3: Static spreadsheets. A spreadsheet from last month is already wrong. Automate the data pull and focus on changes.

Mistake 4: No export workflow. If you can't export in a usable format, you're wasting time re-formatting for your pipeline model every week.

Tools for BD Pipeline Tracking

There are three categories of tools:

1. Enterprise databases (Citeline, GlobalData): Comprehensive but expensive ($10K–$50K/year). Overkill for individual BD analysts.
2. CT.gov + Excel: Free but manual. Works for occasional checks, not weekly tracking.
3. AI-powered tools (TrialScope, etc.): Mid-tier pricing ($49–$129/month), automated data pulls, AI analysis, structured export. Best fit for individual BD professionals and small teams.

For most BD teams, option 3 is the sweet spot — enterprise-grade intelligence at a price individuals can justify.

Conclusion

BD pipeline tracking doesn't have to consume 4+ hours per week. The tools exist to automate the tedious parts — data fetching, filtering, change detection, and structured export.

The teams that win are the ones who spend their time on analysis and decisions, not data collection. Automate the rest.